来曲唑治疗晚期乳腺癌的临床应用研究

Clinical Application of Letrozole in the Treatment of Advanced Breast Cancer

目的 分析来曲唑治疗晚期乳腺癌的临床应用。方法 研究开展时间在2020年7月至2022年5月,将在该时间段内我院收治的70例晚期乳腺癌患者作为研究对象,按照随机数表法将参与研究的患者分为观察组(n=35,采取来曲唑治疗)与对照组(n=35,采取氨鲁米特治疗)。对比两组的临床疗效、肿瘤标志物水平、不良反应发生情况、子宫内膜厚度变化情况和血常规水平方面的差异。结果 观察组临床总缓解率、疾病控制率分别是71.43%、91.43%,均明显高于对照组的45.71%、71.43%(P<0.05)。观察组与对照组的不良反应总发生例数分别为7例、17例,总发生率分别为20.00%、48.57%,两组比较差异有统计学意义(P<0.05)。治疗前观察组与对照组的CA125、CA15-3、CEA、CYFRA21-1指标水平、子宫内膜厚度、WBC、PLT和Hb水平比较存在均衡性,差异无统计学意义(P>0.05);治疗后观察组的CA125、CA15-3、CEA、CYFRA21-1水平均低于对照组,观察组WBC、PLT和Hb水平均高于对照组,子宫内膜厚度观察组小于对照组(P<0.05)。结论 在晚期乳腺癌的临床治疗中,与氨鲁米特治疗相比较而言,来曲唑治疗能够提升临床缓解率和疾病控制率,降低肿瘤标志物水平,减少不良反应,改善子宫内膜厚度,并且对造血功能的损伤更小。

Objective To analyze the clinical application of letrozole in the treatment of advanced breast cancer. Methods The study was carried out from July 2020 to May 2022. Seventy patients with advanced breast cancer who were treated in our hospital during this period were taken as research objects.According to the random number table, the patients participating in the study were divided into the observation group(n=35, treated with letrozole) and the control group(n=35, treated with aminoglutethimide). The clinical efficacy of the two groups was compared. Results The clinical efficacy, tumor marker level, adverse reactions, changes in endometrial thickness and blood routine test level of the two groups were compared and analyzed. The total clinical remission rate and disease control rate of 71.43% and 91.43% in the observation group were significantly higher than 45.71% and 71.43% in the control group(P<0.05). The total number of adverse reactions was 7 cases in the observation group and 17 cases in the control group, with a total incidence of 20.00% and 48.57%, respectively. There was a statistically significant difference between the two groups(P<0.05). Before treatment, the levels of CA125, CA15-3, CEA, CYFRA21-1, endometrial thickness, WBC, PLT, and Hb in the observation group were balanced compared with those in the control group, with no statistically significant difference(P>0.05). After treatment, the levels of the CA125, CA15-3, CEA, CYFRA21-1 indicators in the observation group were lower than those in the control group, the levels of the WBC, PLT, Hb indicators in the observation group were higher than those in the control group, and the endometrial thickness in the observation group was lower than that in the control group(P<0.05). Conclusion In the clinical treatment of advanced breast cancer, compared with aminoglutethimide, letrozole treatment can improve the clinical remission rate and disease control rate, reduce the level of tumor markers, reduce adverse reactions, improve endometrial thickness, and have less damage to hematopoietic function.